ITRM Quote, Financials, Valuation and Earnings

Cosmo Pharmaceuticals NV has a net margin of -2302.31% compared to Iterum Therapeutics Plc's net margin of --. Iterum Therapeutics Plc's return on equity of -- beat Cosmo Pharmaceuticals NV's return on equity of 15.06%.

Iterum Therapeutics Plc has a consensus price target of $5.50, signalling upside risk potential of 2494.34%. On the other hand Cosmo Pharmaceuticals NV has an analysts' consensus of -- which suggests that it could fall by --. Given that Iterum Therapeutics Plc has higher upside potential than Cosmo Pharmaceuticals NV, analysts believe Iterum Therapeutics Plc is more attractive than Cosmo Pharmaceuticals NV.

Iterum Therapeutics Plc has a beta of 2.969, which suggesting that the stock is 196.931% more volatile than S&P 500. In comparison Cosmo Pharmaceuticals NV has a beta of 0.402, suggesting its less volatile than the S&P 500 by 59.833%.

Iterum Therapeutics Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cosmo Pharmaceuticals NV offers a yield of 2.85% to investors and pays a quarterly dividend of $2.34 per share. Iterum Therapeutics Plc pays -- of its earnings as a dividend. Cosmo Pharmaceuticals NV pays out 24.72% of its earnings as a dividend. Cosmo Pharmaceuticals NV's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Iterum Therapeutics Plc quarterly revenues are $390K, which are larger than Cosmo Pharmaceuticals NV quarterly revenues of --. Iterum Therapeutics Plc's net income of -$9M is higher than Cosmo Pharmaceuticals NV's net income of --. Notably, Iterum Therapeutics Plc's price-to-earnings ratio is -- while Cosmo Pharmaceuticals NV's PE ratio is 38.26x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Iterum Therapeutics Plc is 19.91x versus 13.09x for Cosmo Pharmaceuticals NV. Usually stocks with elevated PS ratios are considered overvalued.

GH Research Plc has a net margin of -2302.31% compared to Iterum Therapeutics Plc's net margin of --. Iterum Therapeutics Plc's return on equity of -- beat GH Research Plc's return on equity of -16.86%.

Iterum Therapeutics Plc has a consensus price target of $5.50, signalling upside risk potential of 2494.34%. On the other hand GH Research Plc has an analysts' consensus of $33.48 which suggests that it could grow by 114.71%. Given that Iterum Therapeutics Plc has higher upside potential than GH Research Plc, analysts believe Iterum Therapeutics Plc is more attractive than GH Research Plc.

Iterum Therapeutics Plc has a beta of 2.969, which suggesting that the stock is 196.931% more volatile than S&P 500. In comparison GH Research Plc has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Iterum Therapeutics Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. GH Research Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Iterum Therapeutics Plc pays -- of its earnings as a dividend. GH Research Plc pays out -- of its earnings as a dividend.

Iterum Therapeutics Plc quarterly revenues are $390K, which are larger than GH Research Plc quarterly revenues of --. Iterum Therapeutics Plc's net income of -$9M is higher than GH Research Plc's net income of -$14M. Notably, Iterum Therapeutics Plc's price-to-earnings ratio is -- while GH Research Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Iterum Therapeutics Plc is 19.91x versus -- for GH Research Plc. Usually stocks with elevated PS ratios are considered overvalued.

Jazz Pharmaceuticals Plc has a net margin of -2302.31% compared to Iterum Therapeutics Plc's net margin of 22.33%. Iterum Therapeutics Plc's return on equity of -- beat Jazz Pharmaceuticals Plc's return on equity of -9.16%.

Iterum Therapeutics Plc has a consensus price target of $5.50, signalling upside risk potential of 2494.34%. On the other hand Jazz Pharmaceuticals Plc has an analysts' consensus of $219.40 which suggests that it could grow by 27.42%. Given that Iterum Therapeutics Plc has higher upside potential than Jazz Pharmaceuticals Plc, analysts believe Iterum Therapeutics Plc is more attractive than Jazz Pharmaceuticals Plc.

Iterum Therapeutics Plc has a beta of 2.969, which suggesting that the stock is 196.931% more volatile than S&P 500. In comparison Jazz Pharmaceuticals Plc has a beta of 0.260, suggesting its less volatile than the S&P 500 by 73.986%.

Iterum Therapeutics Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Jazz Pharmaceuticals Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Iterum Therapeutics Plc pays -- of its earnings as a dividend. Jazz Pharmaceuticals Plc pays out -- of its earnings as a dividend.

Iterum Therapeutics Plc quarterly revenues are $390K, which are smaller than Jazz Pharmaceuticals Plc quarterly revenues of $1.1B. Iterum Therapeutics Plc's net income of -$9M is lower than Jazz Pharmaceuticals Plc's net income of $251.4M. Notably, Iterum Therapeutics Plc's price-to-earnings ratio is -- while Jazz Pharmaceuticals Plc's PE ratio is 15.09x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Iterum Therapeutics Plc is 19.91x versus 2.53x for Jazz Pharmaceuticals Plc. Usually stocks with elevated PS ratios are considered overvalued.

Prothena Corp. Plc has a net margin of -2302.31% compared to Iterum Therapeutics Plc's net margin of -102804.76%. Iterum Therapeutics Plc's return on equity of -- beat Prothena Corp. Plc's return on equity of -66.9%.

Iterum Therapeutics Plc has a consensus price target of $5.50, signalling upside risk potential of 2494.34%. On the other hand Prothena Corp. Plc has an analysts' consensus of $20.50 which suggests that it could grow by 127.27%. Given that Iterum Therapeutics Plc has higher upside potential than Prothena Corp. Plc, analysts believe Iterum Therapeutics Plc is more attractive than Prothena Corp. Plc.

Iterum Therapeutics Plc has a beta of 2.969, which suggesting that the stock is 196.931% more volatile than S&P 500. In comparison Prothena Corp. Plc has a beta of -0.113, suggesting its less volatile than the S&P 500 by 111.323%.

Iterum Therapeutics Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Prothena Corp. Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Iterum Therapeutics Plc pays -- of its earnings as a dividend. Prothena Corp. Plc pays out -- of its earnings as a dividend.

Iterum Therapeutics Plc quarterly revenues are $390K, which are larger than Prothena Corp. Plc quarterly revenues of $21K. Iterum Therapeutics Plc's net income of -$9M is higher than Prothena Corp. Plc's net income of -$21.6M. Notably, Iterum Therapeutics Plc's price-to-earnings ratio is -- while Prothena Corp. Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Iterum Therapeutics Plc is 19.91x versus 50.14x for Prothena Corp. Plc. Usually stocks with elevated PS ratios are considered overvalued.